What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
- 23 September 2008
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 5 (11) , 584-585
Abstract
This Practice Point commentary discusses the paper by Horwitz and colleagues, which reported the long-term results of the RTOG 92-02 trial in which patients with locally advanced, node-negative prostate cancer who were treated with neoadjuvant–concurrent hormone ablation therapy and external beam radiation therapy (70 Gy) were subsequently randomized to receive either no further androgen deprivation or long-term (2-year) goserelin therapy. The results at 10 years confirm biochemical and clinical outcome benefits with the use of long-term androgen deprivation therapy for patients treated with conventional-dose radiotherapy. How these results should best be incorporated into dose-escalated radiotherapeutic approaches remains unclear, however, and this issue requires further investigation.Keywords
This publication has 8 references indexed in Scilit:
- Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02European Urology, 2008
- Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate CancerEuropean Urology, 2008
- Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate CancerJournal of Clinical Oncology, 2008
- Does Adjuvant Hormonal Therapy Improve Freedom From Biochemical Relapse in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of RTOG 94-06International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—Results of the randomized EORTC Phase III trial 22961Journal of Clinical Oncology, 2007
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialThe Lancet Oncology, 2007
- Androgen Deprivation Therapy Does Not Impact Cause-Specific or Overall Survival in High-Risk Prostate Cancer Managed With Brachytherapy and Supplemental External BeamInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- No Apparent Benefit at 5 Years From a Course of Neoadjuvant/Concurrent Androgen Deprivation for Patients With Prostate Cancer Treated With a High Total Radiation DoseJournal of Urology, 2003